In SCHOLAR (Safety of Continuing Chemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2), 20 women with HER2-positive breast cancer, LVEF between 40% and 54%, or a decline in LVEF of ≥15% from baseline were enrolled to examine whether it is safe to continue trastuzumab despite mild cardiotoxicity. This evidence concerns the gene ERBB2 and breast carcinoma.